

## EFFICACY AND TOLERANCE EVALUATION OF A TOPICAL "ANTIAGE" FACE DAY CREAM: COMPARISON WITHIN SUBJECTS VERSUS REFERENCE PRODUCT (HALF FACE METHOD - DOUBLE BLIND STUDY)

TEST CODE: E0613 PROTOCOL: 2231

## ABSTRACT STUDY OBJECTIVE

The purpose of this study was to evaluate the *in vivo* "anti-age" efficacy of two day creams (test product vs. reference product) within the same group of healthy female subjects, aged 40 to 55 years, with face rhytidosis (split-face design). Objective measurements by non–invasive instruments, dermatological evaluation as well as subjective evaluation by subjects themselves were used.

The products were used continuously for 4 weeks.

## STUDY METHODOLOGY

This was a 4-week, single-centric, randomised, double-blind, split-face comparative study, carried out under dermatological control.

The study included:

- a baseline visit with short term evaluation of the effect on cutaneous blood microcirculation 10 minutes after the first product application
- an intermediate visit after 2 weeks (T2w)
- and a final visit after 4 weeks (T4w).

During both intermediate and final visits the dermatologist carried out clinical evaluations of the main aging parameters and instrumental evaluations through cutaneous bioengineering methods supported by computerized image analysis.

## **CONCLUSIONS**

Clinical and instrumental results clearly demonstrate an anti-age efficacy after 4 weeks of use of the test product:

- a statistically and clinically significant moisturizing effect,
- a statistically and clinically significant anti-wrinkles efficacy (wrinkles around the eyes less deep and visible).
- a statistically and clinically significant elasticizing effect

Furthermore a statistically and clinically significant effect of the test product on the *superficial skin microcirculation* was demonstrated after one application: + 67,7% (Laser Doppler Flowmetry). This was not detected with the reference product.

Most volunteers confirmed an "anti-age" activity of the tested product in their self-assessment.

Research Director: Dr. Adele Sparavigna, Dermatologist

berming® 8.ml

Derming srl Unipersonale Viale Cesare Battisti, 38 20900 Monza (MB) P.I. e C.F.: 02918050960